Moreover, to our knowledge, there is no study comparing the cost-effectiveness of the three CDK4/6 inhibitors altogether in the first-line treatment of HR+/HER2- advanced breast cancer; the previously mentioned one was a comparison in the second-line treatment (21). Here, ERBB2 is linked to breast cancer.